source
- Regeneron halts Phase 1/2 uveitis antibody trial over unfavorable risk-benefit profileRegeneron has stopped a Phase 1/2 study of its anti‑inflammatory antibody REGN7041 in non‑infectious uveitis, citing an unfavorable benefit‑risk assessment. The antibody targets CD3 on immune cell…
- Amylyx reports Phase 3 success for avexitide in post-bariatric hypoglycemiaAmylyx announced a late-stage success for avexitide, a GLP-1 receptor antagonist, in a Phase 3 trial targeting post-bariatric hypoglycemia. The trial results showed the drug achieved its primary e…